BALTIMORE, Sept. 30 /PRNewswire/ -- The American Foundation for Urologic Disease, (A.F.U.D.) announced today that actor Gavin MacLeod, who is best known for his TV roles as Murray Slaughter on the Mary Tyler Moore Show and Captain Merrill Stubing of The Love Boat, will be serving as the national spokesperson for the "Chart A New Course For Your Health" impotence awareness campaign. The "Chart A New Course For Your Health" consumer awareness campaign is funded through an educational grant provided by VIVUS, Inc.
GREAT NECK, N.Y., Oct. 24 /PRNewswire/ -- Robert M. Cohen & Company analyst Keith R. Bossey reiterated his speculative buy rating on Vivus, Inc. (NASDAQ:VVUS) and continued his 6-month price target of $50-1/2 following an announcement that Pfizer (NYSE:PFE) may introduce a competing impotence drug.
Bossey noted, "While we admit that in most cases competition is unfavorable, Pfizer's entry into the impotence market may expand the market for all involved. Although Pfizer's Viagra may be deemed easier to use, we feel Vivus' on demand product will retain its current favorable marketposition."
SAN FRANCISCO, Oct. 28 /PRNewswire/ -- Genesis Merchant Group Securities reiterated its strong buy rating on Vivus, Inc. (NASDAQ:VVUS) and continued its $75 per share price target. According to associate analyst Curtis Hogue, production capacity remains at or above third quarter levels, and Vivus continues to sell all the product produced at its New Jersey facility.
MENLO PARK, Calif.--(BW HealthWire)--Dec. 1, 1997--VIVUS, Inc. (NASDAQ:VVUS) today announced that MUSE(R) (alprostadil), the Company's treatment for erectile dysfunction, has received authorization from the Medicines Control Agency to market MUSE in the United Kingdom.
GREAT NECK, N.Y., Dec. 1 /PRNewswire/ -- Robert M. Cohen & Co. analyst Keith R. Bossey upgraded his rating on Vivus, Inc. (NASDAQ:VVUS) to a buy from speculative buy and maintained his six-month price target of $50.50 per share.
MENLO PARK, Calif.--(BW HealthWire)--Dec. 3, 1997--VIVUS, Inc (NASDAQ:VVUS) today announced the appointment of Michael I. Levitt to the position of vice president, operations. Levitt, who has 21 years of experience in the pharmaceutical industry, served most recently as vice president of global Collagen
operations and general manager of Lipomatrix, Inc., a division of Collagen Corporation.
In his three years with Collagen, Levitt was responsible for global manufacturing and distribution. Prior to his tenure at Collagen, Levitt held various positions at Eli Lilly & Co., from 1976 to 1994, most recently as director of
production operations.
MENLO PARK, Calif.--(BUSINESS WIRE)--Dec. 10, 1997--VIVUS, Inc. (NASDAQ:VVUS) today announced that the Company will be unable to meet its production goals for the fourth quarter. This shortfall results
primarily from the Company's efforts to expand its production capacity into its new 90,000 square foot plant. In an effort to complete construction and focus on international and US regulatory approvals for the new plant, VIVUS has shifted existing equipment and personnel to the new facility.
SAN FRANCISCO, Dec. 10 /PRNewswire/ -- Genesis Merchant Group Securities analyst D. Curtis Hogue downgraded his rating on Vivus, Inc. (Nasdaq-NNM: VVUS) to long-term buy from strong buy based on the uncertainty surrounding the company's ability to manage the transition from one production facility to two facilities.
Hogue noted, "Our 1998 EPS estimates and price target are currently under review, but we anticipate having to lower these numbers significantly. Based on our initial analysis, we estimate an EPS range of $1.30 to $1.50 for 1998."
Hogue is lowering his full year and Q4 estimates for 1997 as well. Product revenue estimates for Q4 1997 are dropping to $28.6 million from $39.5 million and Q4 EPS estimates are being lowered to $0.18 per share from $0.34. "This effectively lowers our 1997 EPS estimate from $1.21 to $1.04 per share," he added.
GREAT NECK, N.Y., Dec. 10 /PRNewswire/ -- Robert M. Cohen & Co. analyst Keith R. Bossey downgraded Vivus, Inc. (NASDAQ:VVUS) to hold from buy following the company's announcement that it will fall significantly short of fourth quarter production goals due to efforts to expand production.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
December 23, 1997 (from the MUSE promotion and education package)
Dear Dr. Primary Physician:
In February, you and your patients will see nationwide television and magazine advertising telling the 20 million men in the U.S. with erectile dysfunction (impotence) that they are not alone in experiencing this treatable, vascular disorder----and that MUSE (alprostadil) is a locally-acting, effective and convenient treatment. The campaign will encourage patients to see a physician for proper diagnosis and treatment of this significant public health condition.
MUSE acts directly to initiate an erection by dilating the penile vasculature. This allows the corpora cavernosa to fill, which is followed by compression of the emissary veins and restriction of venous outflow. For the majority of patients, the result is an erection sufficient for sucessful intercourse.
We have enclosed a brochure which includes examples of the advertising that will appear in the national campaign so that you will be able to respond to patients' questions. Also enclosed are materials that describe MUSE, showing how easy it is for patients to use. Many of your patients will want to join the 400,000 men who have been prescribed MUSE during its first year on the market.
Experts agreee that erectile dysfunction is a local disorder. That helps explain why MUSE----a targeted medication with few systemic side effects and minimal drug-drug interaction potential and with a 5- to 10-minute onset----has become the #1 treatment prescribed by urologists for this indication. Quick, convenient administration allows for the spontaneity that patients prefer.
Thank you for taking the time to review these materials and become better acquainted with MUSE. Please fill out the attached card to receive a copy of the MUSE Product Monograph.
Yours sincerely,
Alfred P. Spivak, M.D.
Director of Medical Services
P.S. MUSE is the local solution to a local problem----non-injectable, easy, discreet, convenient with few systemic side effects.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Just thought I'd recap the past few months, to give a better picture of where we are. You can draw your own conclusions about where we are going.
Zebra |
